CEL-SCI Corp
$ 4.56
3.87%
26 Feb - close price
- Market Cap 36,914,400 USD
- Current Price $ 4.56
- High / Low $ 4.68 / 4.32
- Stock P/E N/A
- Book Value 1.38
- EPS -6.27
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.60 %
- ROE -2.12 %
- 52 Week High 13.48
- 52 Week Low 1.98
About
CEL-SCI Corporation is dedicated to the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia.
Analyst Target Price
$42.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-23 | 2025-08-12 | 2025-05-13 | 2025-01-13 | 2024-12-31 | 2024-08-14 | 2024-05-15 | 2024-02-14 | 2023-12-21 | 2023-08-10 | 2023-05-12 | 2023-02-14 |
| Reported EPS | -0.86 | -1.36 | -2.3323 | -2.7 | -2.7003 | -0.14 | -0.14 | -0.14 | -0.16 | -0.19 | -0.19 | -0.18 |
| Estimated EPS | None | None | None | -3.3 | -0.1 | -0.13 | -0.14 | -0.14 | -0.16 | -0.16 | -0.17 | -0.21 |
| Surprise | 0 | 0 | 0 | 0.6 | -2.6003 | -0.01 | 0 | 0 | 0 | -0.03 | -0.02 | 0.03 |
| Surprise Percentage | None% | None% | None% | 18.1818% | -2600.3% | -7.6923% | 0% | 0% | 0% | -18.75% | -11.7647% | 14.2857% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CVM
2026-02-18 16:26:58
CEL-SCI Corporation reported its fiscal first quarter 2026 results, highlighting plans to commence patient enrollment in a pivotal U.S. FDA head and neck cancer registration study in summer 2026. The company is also actively pursuing entry into the Saudi oncology market for its Multikine therapy, building on previous successful Phase 3 trial results showing significant improvement in survival rates. Financially, CEL-SCI reported a reduced net loss of $5.5 million for the quarter compared to $7.1 million in the prior year, with decreased research and development and general and administrative expenses.
2026-02-18 11:57:34
Cel-Sci Corp. (CVM) reported a loss of $5.5 million in its fiscal first quarter, amounting to 68 cents per share. The report was generated by Automated Insights using data from Zacks Investment Research.
2026-02-17 22:28:09
CEL SCI CORP has released its Form 10-Q report for Q1 fiscal year 2025, detailing a net operating loss of approximately $5.5 million and reduced R&D and G&A expenses. The report highlights promising Phase III trial results for Multikine, an investigational therapy for head and neck cancer, which showed a 73% survival rate for its target population. The company plans a confirmatory registration study and aims for accelerated approval, addressing an unmet medical need for patients with low PD-L1 expression.
2026-02-17 22:28:09
Cel-Sci Corp. reported a net loss of $5.5 million for its fiscal first quarter, which translates to a loss of 68 cents per share. The company, headquartered in Vienna, Virginia, disclosed these financial results outlining its performance for the quarter.
2026-02-17 22:28:09
Cel-Sci Corp. (CVM) reported a loss of $5.5 million in its fiscal first quarter, translating to a loss of 68 cents per share. The Vienna, Virginia-based company's financial results were generated by Automated Insights using data from Zacks Investment Research.
2026-02-17 22:28:09
Cel-Sci Corp. (CVM) reported a loss of $5.5 million in its fiscal first quarter, translating to a loss of 68 cents per share. The company, based in Vienna, Virginia, released these financial results on Tuesday. The information was generated by Automated Insights using data from Zacks Investment Research.
